A Phase 2 interventional study of Goserelin acetate and Goserelin acetate in Advanced Breast Cancer, sponsored by AstraZeneca. Completed at 15 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-01-24.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing goserelin in Breast Neoplasms — 7 open to participants now, 9 under way, none of them phase 3. Goserelin · Breast Neoplasms.
Among the 43 studies testing goserelin in Breast Neoplasms, this one is the 24th largest by enrollment of the 41 interventional ones that give a count, is one of 3 that started in 2006, is one of 21 in phase 2, and was the 9th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →7 of the 43 studies testing goserelin in Breast Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
TerSera Therapeutics LLC · Sites in United States
Ages 18–55 · Women only
Mayo Clinic · Sites in United States
Ages 18–50 · Women only
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Women only
University of Chicago · Sites in Nigeria
Ages 18+ · Women only
Fudan University · Sites in China
Ages 18+ · Women only
By country, each count listing its studies:
Goserelin: first FDA approval 1989 (ZOLADEX). What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 22 · Phase 3 16 · Phase 4 1
First in 1990; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 98 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 147 across the 41 interventional studies. Of the 24 that completed or were terminated, 9 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 43 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
198 studies in Breast Neoplasms by AstraZeneca: 20 open now, 50 under way, 24 of them phase 3. Of 144 finished, 32 (22%) have results posted.
Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 80th largest by enrollment of the 125 interventional ones that give a count, is one of 9 that started in 2006, is one of 31 in phase 2, and was the 30th registered.
AstraZeneca’s Breast Neoplasms studies by the year they started, since 1996.
2 of the studies testing goserelin in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02476786Washington University School of MedicineEndocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score | 2027-01-31 |
| NCT07310420TerSera Therapeutics LLCA Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer | 2027-03-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing goserelin in Breast Neoplasms, from their registry updates:
Among AstraZeneca’s 198 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The primary objective is to evaluate whether Zoladex 10.8 mg (12-weekly) is non-inferior to Zoladex 3.6 mg (4-weekly) in pre-menopausal women with oestrogen receptor positive advanced breast cancer by assessment of progression-free survival at 24 weeks.
Secondary Objectives are to compare the safety and tolerability profile of ZOLADEX 10.8 mg and ZOLADEX 3.6 mg by assessment of adverse events (AEs)and to assess goserelin PK in Japanese and Caucasian participants who have received ZOLADEX 10.8 mg by assessment of goserelin plasma concentration time profiles
Recruitment into the study has been permanently stopped as of 24 December 2007 due to slow recruitment. 98 (vs the planned 260) patients were randomised into the study and will be followed as per protocol for 2 years
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
This study's enrollment of 98 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Compared within Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ZOLADEX (goserelin acetate) 10.8 mg intramuscular depot for injection every 12 weeks
Drug: Goserelin acetate
ZOLADEX (goserelin acetate) 3.6 mg intramuscular depot for injection every 4 weeks
Drug: Goserelin acetate
3.6 mg intramuscular depot injection given every 4 weeks
Also known as: Zoladex®
10.8 mg intramuscular depot injection given every 12 weeks
Also known as: Zoladex®
Percentage of Participants With Progression Free Survival (PFS) at Week 24
The number of participants for whom neither objective disease progression or death (due to any cause) has been observed at Week 24 over the number of randomised participants x 100.
Time frame: Objective tumour assessments carried out every 12 weeks (+/- 7 days) until Week 24, and then every 24 weeks (+/- 14 days) until Week 96 or objective progression is confirmed according to Response Evaluation Criteria in Solid Tumours (RECIST).
Objective Response Rate (ORR) at Week 24
Number of participants who were objective responders at Week 24 over the number of participants evaluable for response x 100. An objective responder = a participants whose best unconfirmed response is either CR (Complete Response Disappearance of all target lesions) or PR (Partial Response At least a 30% decrease in target lesions)
Time frame: Response Evaluation Criteria in Solid Tumours (RECIST) tumour assessments carried out every 12 weeks from randomisation until Week 24 in those patients with measurable disease at baseline.
Oestradiol (E2) Serum Concentrations at Week 24
A comparison of mean E2 serum concentrations at timepoint(s) post Day 1 performed using analysis of covariance (ANCOVA), with treatment group, baseline E2 serum concentrations and country as covariates. Data analysed on the log scale; log scale mean and pooled log scale standard deviation from Analysis of Covariance (ANCOVA) presented.
Time frame: Blood samples for measurement of E2 concentrations collected from all patients at scheduled visits of screening, Day 1 and Weeks 12 and 24 (+/- 7 days). Week 24 data is presented
Maximum Plasma Concentration, Cmax (ng/mL)
Maximum plasma concentration, Cmax (ng/mL), derived from analysis of pharmacokinetic (PK) outcomes samples provided only by participants in the PK subgroup set (all of whom received ZOLADEX 10.8 mg)
Time frame: Blood samples taken at Days 1, 2 and 3, Weeks 4, 12 and 24. Derived from the individual goserelin plasma concentration-time profiles following the first dose of study drug for patients in the pharmacokinetic (PK) subgroup
Time to Maximum Plasma Concentration, Tmax (Hours)
Time to maximum plasma concentration, Tmax (hours), derived from analysis of pharmacokinetic (PK) outcomes samples provided only by participants in the PK subgroup set (all of whom received ZOLADEX 10.8 mg)
Time frame: Blood samples taken at Days 1, 2 and 3, Weeks 4, 12 and 24. Derived from the individual goserelin plasma concentration-time profiles following the first dose of study drug for patients in the pharmacokinetic (PK) subgroup
Area Under the Plasma Concentration Curve (0-12 Weeks)
Area under the plasma concentration curve (0-12 weeks) derived from analysis of pharmacokinetic (PK) outcomes samples provided only by participants in the PK subgroup set (all of whom received ZOLADEX 10.8 mg)
Time frame: Blood samples taken at Days 1, 2 and 3, Weeks 4, 12 and 24. Derived from the individual goserelin plasma concentration-time profiles following the first dose of study drug for patients in the pharmacokinetic (PK) subgroup
Pre-menopausal women with Oestrogen Receptor Positive Advanced Breast Cancer were recruited between 25th April 2006 and 24th December 2007. 49 participants were randomised to ZOLADEX 10.8 mg and 49 participants were randomised to ZOLADEX 3.6 mg. One participant was randomised to ZOLADEX 3.6 mg but received ZOLADEX 10.8 mg.
| Milestone | ZOLADEX 10.8 mg | ZOLADEX 3.6 mg |
|---|---|---|
| Started | 49 | 49 |
| Received study treatment | 50 | 48 |
| Completed | 12 | 16 |
| Not completed | 37 | 33 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 4 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Death | 0 | 2 |
| Withdrew: Disease progression | 30 | 25 |
| Withdrew: Reasons not specified | 5 | 1 |
The number of participants for whom neither objective disease progression or death (due to any cause) has been observed at Week 24 over the number of randomised participants x 100.
| Percentage of participants | ZOLADEX 10.8 mg | ZOLADEX 3.6 mg |
|---|---|---|
| Percentage of Participants With Progression Free Survival (PFS) at Week 24 | 69.4 | 73.5 |
Number of participants who were objective responders at Week 24 over the number of participants evaluable for response x 100. An objective responder = a participants whose best unconfirmed response is either CR (Complete Response Disappearance of all target lesions) or PR (Partial Response At least a 30% decrease in target lesions)
| Percentage of participants | ZOLADEX 10.8 mg | ZOLADEX 3.6 mg |
|---|---|---|
| Objective Response Rate (ORR) at Week 24 | 28.9 | 25.6 |
A comparison of mean E2 serum concentrations at timepoint(s) post Day 1 performed using analysis of covariance (ANCOVA), with treatment group, baseline E2 serum concentrations and country as covariates. Data analysed on the log scale; log scale mean and pooled log scale standard deviation from Analysis of Covariance (ANCOVA) presented.
| pmol/L | ZOLADEX 10.8 mg | ZOLADEX 3.6 mg |
|---|---|---|
| Oestradiol (E2) Serum Concentrations at Week 24 | 1.42 ± 0.99 | 1.49 ± 0.99 |
Maximum plasma concentration, Cmax (ng/mL), derived from analysis of pharmacokinetic (PK) outcomes samples provided only by participants in the PK subgroup set (all of whom received ZOLADEX 10.8 mg)
| ng/mL | ZOLADEX 10.8 mg | ZOLADEX 3.6 mg |
|---|---|---|
| Maximum Plasma Concentration, Cmax (ng/mL) | 4.565 (0.501 to 14.000) | — |
Time to maximum plasma concentration, Tmax (hours), derived from analysis of pharmacokinetic (PK) outcomes samples provided only by participants in the PK subgroup set (all of whom received ZOLADEX 10.8 mg)
| hours | ZOLADEX 10.8 mg | ZOLADEX 3.6 mg |
|---|---|---|
| Time to Maximum Plasma Concentration, Tmax (Hours) | 1.9 (1 to 24) | — |
Area under the plasma concentration curve (0-12 weeks) derived from analysis of pharmacokinetic (PK) outcomes samples provided only by participants in the PK subgroup set (all of whom received ZOLADEX 10.8 mg)
| ng/mL | ZOLADEX 10.8 mg | ZOLADEX 3.6 mg |
|---|---|---|
| Area Under the Plasma Concentration Curve (0-12 Weeks) | 33.021 (9.13 to 73.70) | — |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ZOLADEX 10.8 mg | — | 2/50 (4%) | 39/50 (78%) |
| ZOLADEX 3.6 mg | — | 3/48 (6.3%) | 37/48 (77.1%) |
| Event | ZOLADEX 10.8 mg | ZOLADEX 3.6 mg |
|---|---|---|
| Peritonsillar AbscessInfections and infestations | 0/50 | 1/48 |
| Endometrial HyperplasiaReproductive system and breast disorders | 1/50 | 1/48 |
| HaematomaVascular disorders | 0/50 | 1/48 |
| Humerus FractureInjury, poisoning and procedural complications | 1/50 | 0/48 |
| Event | ZOLADEX 10.8 mg | ZOLADEX 3.6 mg |
|---|---|---|
| Hot FlushVascular disorders | 19/50 | 18/48 |
| AmenorrhoeaReproductive system and breast disorders | 13/50 | 11/48 |
| NasopharyngitisInfections and infestations | 11/50 | 5/48 |
| Weight IncreasedInfections and infestations | 7/50 | 8/48 |
| NauseaGastrointestinal disorders | 3/50 | 4/48 |
| FatigueGeneral disorders | 0/50 | 4/48 |
| PyrexiaGeneral disorders | 1/50 | 4/48 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/50 | 4/48 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/50 | 4/48 |
| HeadacheNervous system disorders | 4/50 | 3/48 |
| Age Continuous(Years) | ZOLADEX 10.8 mg | ZOLADEX 3.6 mg | Total |
|---|---|---|---|
| Mean | 42.0 ± 6.45 | 42.6 ± 6.07 | 42.3 ± 6.24 |
| Sex: Female, Male(Participants) | ZOLADEX 10.8 mg | ZOLADEX 3.6 mg | Total |
|---|---|---|---|
| Female | 49 | 49 | 98 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | ZOLADEX 10.8 mg | ZOLADEX 3.6 mg | Total |
|---|---|---|---|
| Caucasian | 27 | 32 | 59 |
| Black | 0 | 0 | 0 |
| Oriental | 22 | 17 | 39 |
| Other | 0 | 0 | 0 |
The record gives a start of Apr 2006 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Goserelin